Participant flow

Paclitaxel, Ifosfamide, and Carboplatin Followed By Autologous Stem Cell Transplant in Treating Patients With Germ Cell Tumors That Did Not Respond to Cisplatin · Source last updated 2016-05-18

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

groups

1. description

   This is a phase I/II trial of sequential accelerated chemotherapy cycles with paclitaxel/ifosfamide and paclitaxel/ifosfamide and carboplatin administered with G-CSF and PBSC support. During phase I, carboplatin, ifosfamide, and paclitaxel will be dose escalated to determine the MTD. Additional patients will be enrolled in the Phase II portion of the study following the determination of the MTD of Ifosfamide and paclitaxel, to bring the total possible number of patients treated at the MTD to 38. filgrastim carboplatin ifosfamide paclitaxel autologous hematopoietic stem cell transplantation peripheral blood stem cell transplantation

   id

   FG000

   title

   Chemotherapy With Stem Cell Support

periods

1. drop Withdraws

   1. reasons

      1. group Id

         FG000

         num Subjects

         3

      type

      Removed pior to the high-dose portion

   milestones

   1. achievements

      1. group Id

         FG000

         num Subjects

         26

      type

      STARTED

   2. achievements

      1. group Id

         FG000

         num Subjects

         23

      type

      COMPLETED

   3. achievements

      1. group Id

         FG000

         num Subjects

         3

      type

      NOT COMPLETED

   title

   Overall Study

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice